JP2017502092A - ヘテロアリール及びその使用 - Google Patents

ヘテロアリール及びその使用 Download PDF

Info

Publication number
JP2017502092A
JP2017502092A JP2016563905A JP2016563905A JP2017502092A JP 2017502092 A JP2017502092 A JP 2017502092A JP 2016563905 A JP2016563905 A JP 2016563905A JP 2016563905 A JP2016563905 A JP 2016563905A JP 2017502092 A JP2017502092 A JP 2017502092A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
hydrogen
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016563905A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502092A5 (enExample
Inventor
インドゥ ティー． バラサン，
インドゥ ティー． バラサン，
クリス ブラックバーン，
クリス ブラックバーン，
ジェフリー ピー． シャバーリ，
ジェフリー ピー． シャバーリ，
ジョーハラ チューター，
ジョーハラ チューター，
コートニー エー． クリス，
コートニー エー． クリス，
ナタリー ダモーレ，
ナタリー ダモーレ，
ポール イー． フレミング，
ポール イー． フレミング，
ケネス エム． ギグスタッド，
ケネス エム． ギグスタッド，
クリスタ イー． ギプソン，
クリスタ イー． ギプソン，
マリオ ジラード，
マリオ ジラード，
ヨンボ フー，
ヨンボ フー，
ジャニス リー，
ジャニス リー，
ギャン リー，
ギャン リー，
マンソレ レザイ，
マンソレ レザイ，
マイケル ディー． シンチャック，
マイケル ディー． シンチャック，
フランソワ ソーシー，
フランソワ ソーシー，
スティーブン ジー． ストラウド，
スティーブン ジー． ストラウド，
トリシア ジェイ． ヴォス，
トリシア ジェイ． ヴォス，
ヒ シュー，
ヒ シュー，
インチュン イエ，
インチュン イエ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2017502092A publication Critical patent/JP2017502092A/ja
Publication of JP2017502092A5 publication Critical patent/JP2017502092A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2016563905A 2014-01-14 2015-01-13 ヘテロアリール及びその使用 Pending JP2017502092A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461927064P 2014-01-14 2014-01-14
US61/927,064 2014-01-14
US201462054757P 2014-09-24 2014-09-24
US62/054,757 2014-09-24
PCT/US2015/011250 WO2015108881A1 (en) 2014-01-14 2015-01-13 Heteroaryls and uses thereof

Publications (2)

Publication Number Publication Date
JP2017502092A true JP2017502092A (ja) 2017-01-19
JP2017502092A5 JP2017502092A5 (enExample) 2018-02-08

Family

ID=53543368

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016563905A Pending JP2017502092A (ja) 2014-01-14 2015-01-13 ヘテロアリール及びその使用

Country Status (4)

Country Link
US (1) US10202373B2 (enExample)
EP (1) EP3094326A4 (enExample)
JP (1) JP2017502092A (enExample)
WO (1) WO2015108881A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2016000270A1 (en) 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.
EP3094326A4 (en) 2014-01-14 2017-07-26 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
LT3416957T (lt) 2016-02-19 2020-11-25 Sprint Bioscience Ab 6-heterociklil-4-morfolin-4-ilpiridin-2-ono junginiai, tinkami vėžio ir diabeto gydymui
AU2017219846B2 (en) 2016-02-19 2021-05-13 Sprint Bioscience Ab 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes
CN116589461A (zh) * 2017-08-23 2023-08-15 思普瑞特生物科学公司 氮杂吲哚基吡啶酮化合物和二氮杂吲哚基吡啶酮化合物
IL302077A (en) 2017-08-23 2023-06-01 Sprint Bioscience Ab Morpholinylpyridone compounds
IL302293A (en) 2017-08-23 2023-06-01 Sprint Bioscience Ab Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
EP4056556A1 (en) 2017-08-23 2022-09-14 Sprint Bioscience AB Pyridylpyridone compounds
WO2021050824A1 (en) 2019-09-11 2021-03-18 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
JP2024532780A (ja) * 2021-08-13 2024-09-10 デシフェラ・ファーマシューティカルズ，エルエルシー Ｖｐｓ３４阻害剤を使用した併用療法
WO2024061371A1 (zh) * 2022-09-23 2024-03-28 广州威诺森医药科技有限公司 一种骈环吡啶类甾体合成酶抑制剂及其制备方法和应用
EP4615843A1 (en) * 2022-11-10 2025-09-17 «Target Medicals» Limited Liability Company Inhibitors of human aldosterone synthase (cyp11b2)

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003286876A1 (en) 2002-11-01 2004-06-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1685124A1 (en) 2003-11-10 2006-08-02 MERCK SHARP & DOHME LTD. Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
CA2585490A1 (en) 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
EP1831168B1 (en) 2004-12-16 2014-07-02 Vertex Pharmaceuticals Inc. Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases.
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
EP2029593A1 (en) 2006-05-22 2009-03-04 AstraZeneca AB Indole derivatives
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
SG174086A1 (en) 2006-08-30 2011-09-29 Cellzome Ltd Triazole derivatives as kinase inhibitors
ES2363178T3 (es) 2006-12-04 2011-07-26 Astrazeneca Ab Compuestos de urea policíclicos antibacterianos.
AU2007336933A1 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
WO2009013348A2 (en) 2007-07-26 2009-01-29 Novartis Ag Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
ES2401557T3 (es) 2007-08-02 2013-04-22 Amgen, Inc Moduladores de Pl3 cinasas y métodos de uso
WO2009039140A1 (en) 2007-09-17 2009-03-26 Smithkline Beecham Corporation Pyridopyrimidine derivatives as pi3 kinase inhibitors
EP2211615A4 (en) 2007-10-22 2010-10-13 Glaxosmithkline Llc PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
CL2008003798A1 (es) 2007-12-19 2009-10-09 Amgen Inc Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
EP2307400B1 (en) 2008-05-30 2014-04-23 Amgen, Inc Inhibitors of pi3 kinase
ES2566339T3 (es) 2008-06-05 2016-04-12 Glaxo Group Limited Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
EP2311842A3 (en) 2008-06-24 2011-07-13 Takeda Pharmaceutical Company Limited PI3K/M TOR inhibitors
WO2010007100A1 (en) 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
AU2009279787B2 (en) 2008-08-04 2014-05-29 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US20110212977A1 (en) 2008-11-11 2011-09-01 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
WO2010057877A1 (en) * 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
US8071605B2 (en) 2008-12-12 2011-12-06 Astrazeneca Ab Piperidine compounds for use in the treatment of bacterial infections
CN102459249A (zh) 2009-05-22 2012-05-16 埃克塞里艾克西斯公司 作为PI3K/mTOR抑制剂的苯并氧氮杂环庚三烯以及它们使用与制造方法
CA2767089A1 (en) * 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
CN102471310A (zh) 2009-09-04 2012-05-23 诺瓦提斯公司 用于治疗增生性疾病的联吡啶化合物
EA201201081A1 (ru) 2010-02-05 2013-03-29 Мерк Патент Гмбх Производные гетарил[1,8]нафтиридина
WO2012003912A1 (en) 2010-07-05 2012-01-12 Merck Patent Gmbh Bipyridyl derivatives useful for the treatment of kinase - induced diseases
WO2012009227A1 (en) 2010-07-16 2012-01-19 N30 Pharmaceuticals, Llc Novel dihydropyridin-2(1h)-one compounds as s-nitrosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists
CN103209960A (zh) 2010-07-26 2013-07-17 百时美施贵宝公司 用作cyp17抑制剂的磺酰胺化合物
US8478700B2 (en) 2010-08-11 2013-07-02 Brightedge Technologies, Inc. Opportunity identification and forecasting for search engine optimization
PH12013500274A1 (en) 2010-08-11 2013-03-04 Millennium Pharm Inc Heteroaryls and uses thereof
JP2013533318A (ja) 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリールおよびその使用
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
EA201390717A1 (ru) 2010-11-17 2013-10-30 Новартис Аг 3-(аминоарил)пиридиновые соединения
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
WO2012085815A1 (en) 2010-12-21 2012-06-28 Novartis Ag Bi-heteroaryl compounds as vps34 inhibitors
HUE024504T2 (en) 2010-12-23 2016-01-28 Sanofi Sa Pyrimidine derivatives, a process for their preparation and their use in medicine
US20130303507A1 (en) 2011-01-28 2013-11-14 Novartis Ag Substituted hetero-biaryl compounds and their uses
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
DE102011077104A1 (de) 2011-06-07 2012-12-13 Siemens Aktiengesellschaft Verfahren zur Gewinnung von metallhaltigen Wertstoffen aus einem metallhaltige Wertstoffe enthaltenden suspensionsartigen Massestrom
KR101502500B1 (ko) 2011-07-01 2015-03-16 주식회사 엘지화학 비수 전해액 및 이를 이용한 리튬 이차전지
UA111382C2 (uk) 2011-10-10 2016-04-25 Оріон Корпорейшн Інгібітори протеїнкінази
WO2013096642A1 (en) 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2013126608A1 (en) 2012-02-22 2013-08-29 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as tnap inhibitors
CA2873861C (en) 2012-04-05 2021-01-19 Boehringer Ingelheim International Gmbh Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
EP2903613B1 (en) 2012-10-08 2017-11-22 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of irak4 activity
WO2014083327A1 (en) 2012-11-27 2014-06-05 Md Pharma Ab Adenine derivatives suitable for the treatment of (inter alia) muscular dystrophy
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
CN104903320B (zh) 2013-01-11 2018-11-13 富士胶片株式会社 含氮杂环化合物或其盐
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
EP3094326A4 (en) 2014-01-14 2017-07-26 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TN2016000270A1 (en) 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol. 50, no. 1, JPN6018035201, 2007, pages 65 - 73, ISSN: 0004006841 *

Also Published As

Publication number Publication date
US20160333007A1 (en) 2016-11-17
EP3094326A1 (en) 2016-11-23
US10202373B2 (en) 2019-02-12
WO2015108881A1 (en) 2015-07-23
EP3094326A4 (en) 2017-07-26

Similar Documents

Publication Publication Date Title
JP2017502092A (ja) ヘテロアリール及びその使用
ES2908042T3 (es) Heteroarilos y usos de los mismos
AU2015203480B2 (en) Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor
DK2497772T3 (en) A compound for inhibiting mitotic progression
EP2373657B1 (en) 5,7-dihydro-6h-pyrimido[5,4-d][1]benzazepin-6-thiones as plk inhibitors
AU2019209470A1 (en) Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN105461714B (zh) 并环类pi3k抑制剂
EP3035800A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN107278202A (zh) 用于治疗炎症和癌症的杂环itk抑制剂
CN107921044B (zh) 用于治疗疾病的gls1抑制剂
JP2015506347A (ja) ヘテロアリールおよびその使用
WO2012022265A1 (en) Pyrrolopyrimidine compounds and uses thereof
CN104411706B (zh) 咪唑酮类衍生物、其药物组合物和用途
CA3095367A1 (en) Imidazopiperazine inhibitors of transcription activating proteins
WO2020078362A1 (zh) 一类咪唑并芳环类化合物的制备和应用
CA3078942A1 (en) Pyrrolotriazine compounds and methods of inhibiting tam kinases
HK40121672A (zh) 杂芳基杂环化合物及其用途
HK40074266B (zh) 杂芳基杂环化合物及其用途
HK1227295A1 (en) Heteroaryls and uses thereof
HK1163072B (en) 5, 7-dihydro-6h-pyrimido[5, 4-d][1]benzazepin-6-thiones as plk inhibitors
HK1185067A (en) Hetarylaminonaphthyridines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171218

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190329